


**REMARKS/ARGUMENTS**

With this amendment, Applicants respectfully request cancellation of Original Figures 1 and 3. Applicants also respectfully request entry of amendments to the specification to reflect the cancellation of original Figures 1 and 3 and renumbering of original Figures 2, 4, and 5; as amended Figures 1, 2, and 3, respectively. Applicants assert that the results depicted in original Figure 1 are described in Example III, page 65 in the paragraph beginning at line 19. Applicants also assert that the results depicted in original Figure 3 are described in Example IV, page 66 in the paragraph beginning at line 4. Thus, even after cancellation of original Figures 1 and 3, the information depicted therein is disclosed in the specification.

**CONCLUSION**

Entry of this amendment is respectfully urged since it merely cures a formal defect in original Figures 1 and 3 and does not touch the merits.

Respectfully submitted,



Beth L. Kelly  
Reg. No. 51,868



TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
Attachments  
BLK:blk  
60207732 v1



*Cancelled*

~~Figure 1~~

Specific Polyclonal antibodies for ING2 and ING1 by ELISA





<sup>1</sup>  
~~Figure 2~~






*Canceled*  
~~Figure 3~~

ING2 inhibits cell growth of HCT116 cell line by Colony Formation Assay.

We constructed ING2 and anti-ING2 mammalian expression vectors (CMV promoter, Neomycin resistant). We transfected them into human colon cancer cell line, HCT116. Transfected cells were selected by Neomycin and ING2 inhibitory effect for cell growth was determined by Colony Formation Assay.

HCT116: human, hereditary non-polyposis colon cancer cell line, wt p53



Colony number

+++


+++

+




Figure <sup>2</sup>/<sub>4</sub>

p33ING2 protein was induced by topoisomerase II inhibitor, etoposide.  
(p33ING1 was not induced.)





RKO  
pcDNA3.1 (control)



Sync Wizard Model


Date acquired: 20-Jul-99  
File: RKO P 4-1ug 2days  
Source: RKO P 4-1ug 2days  
Case: PATIENT ID  
Analysis type: Manual analysis  
Prep: Unknown

G0G1: 43.13 % Mean: 92.50  
CV: 5.03 %  
G2M: 32.50 % Mean: 175.58  
G2/G1: 1.91  
S-Phase: 24.38 % Mean: 134.93

Compartment 1: 24.38 %

Modeled Events: 7650  
RCS: 5.831

RKO  
p33ING1



Sync Wizard Model


Date acquired: 20-Jul-99  
File: RKO ING1 4-1ug 2days  
Source: RKO ING1 4-1ug 2days  
Case: PATIENT ID  
Analysis type: Manual analysis  
Prep: Unknown

G0G1: 67.14 % Mean: 106.56  
CV: 5.60 %  
G2M: 21.67 % Mean: 198.20  
G2/G1: 1.86  
S-Phase: 11.18 % Mean: 152.86

Compartment 1: 11.18 %

Modeled Events: 3732  
RCS: 4.762

RKO  
p33ING2



Sync Wizard Model

Date acquired: 20-Jul-99  
File: RKO ING2 4-1ug 2days  
Source: RKO ING2 4-1ug 2days  
Case: PATIENT ID  
Analysis type: Manual analysis  
Prep: Unknown

G0G1: 71.18 % Mean: 105.68  
CV: 4.77 %  
G2M: 19.97 % Mean: 198.00  
G2/G1: 1.67  
S-Phase: 8.85 % Mean: 152.28

Compartment 1: 8.85 %

Modeled Events: 10047  
RCS: 3.209